BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/31/2021 6:51:25 AM | Browse: 535 | Download: 1273
 |
Received |
|
2021-03-18 15:38 |
|
Peer-Review Started |
|
2021-03-18 15:42 |
|
First Decision by Editorial Office Director |
|
2021-04-23 18:33 |
|
Return for Revision |
|
2021-04-23 18:33 |
|
Revised |
|
2021-05-03 17:44 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2021-07-14 03:31 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2021-07-14 07:06 |
|
Articles in Press |
|
2021-07-14 07:06 |
|
Edit the Manuscript by Language Editor |
|
2021-07-25 23:11 |
|
Typeset the Manuscript |
|
2021-08-25 13:25 |
|
Publish the Manuscript Online |
|
2021-08-31 06:51 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Retrospective Study |
| Article Title |
Efficacy evaluation of arbidol in COVID-19 patients: A retrospective study
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Shuo Wei, Sha Xu and Yun-Hu Pan |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Fujian Medical University Sailing Fund |
2016QH121 |
|
| Corresponding Author |
Yun-Hu Pan, MD, Associate Chief Physician, Department of Respiratory Medicine, 907 Hospital of the Joint Logistics Team, No. 99 Binjiang North Road, Nanping 353000, Fujian Province, China. 18750975908@163.com |
| Key Words |
COVID-19; SARS-CoV-2; Arbidol; Treatment; Antiviral |
| Core Tip |
This study indicates the duration course of coronavirus disease 2019 (COVID-19) patients with moderate and severe cases was reduced by 6.183 days when arbidol was administered. Ferritin > 486.5 ng/mL and lactate dehydrogenase (LDH) > 239.5 U/L were independent risk factors for delayed recovery from COVID-19. Early administration of arbidol 200 mg administered orally t.i.d, with a 10-d course of treatment may be an effective management strategy in COVID-19 patients particularly those with increased serum ferritin or elevated LDH. |
| Publish Date |
2021-08-31 06:51 |
| Citation |
Wei S, Xu S, Pan YH. Efficacy evaluation of arbidol in COVID-19 patients: A retrospective study. World J Clin Cases 2021; 9(25): 7350-7357 |
| URL |
https://www.wjgnet.com/2307-8960/full/v9/i25/7350.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v9.i25.7350 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
